Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval. Hangzhou's Huadong Medicine acquired Asia-Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Park, CA, in a $75 million agreement.

Week In Review: U.S. FDA Rejects Innovent/Lilly PD-1 NDA Based On China-Only Trial Subjects

Eli Lilly and Company ( LLY , Financial) announced on Friday that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant of Covid-19.

Eli Lilly Antibody Granted FDA Approval

Eli Lilly & Co. lly said late Friday that the U.S. Food and Drug Administration has issued an emergency-use authorization for bebtelovimab, the pharma company's antibody treatment for COVID-19. Bebtelovimab now can be used for the treatment of mild-to-moderate COVID-19 in adults as well as children older than 12 years of age and over a certain weight who are at high risk of severe COVID-19 and for whom treatment options may be limited.

Lilly's COVID-19 treatment gets FDA's emergency-use approval

The U.S. has ordered 600,000 doses of a new treatment that helps the immune system combat the coronavirus' omicron variant.

FDA Authorizes Eli Lilly Antibody Treatment That Fights Omicron

INDIANAPOLIS, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients. The monoclonal antibody treatment sintilimab injection combined with pemetrexed and platinum chemotherapy is for the first-line treatment of people with non-squamous non-small cell lung cancer.

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analysts. The drug in question, sintilimab, is being developed by Innovent Biologics Inc. 1801, -7.47% , a Chinese drug maker, and Eli Lilly & Co. LLY, -1.56%.

SVB Leerink analyst doesn't expect cancer drug developed by Innovent and Lilly to be approved

An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.

Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab

FDA committee members said the trial population of mostly Asian men did not represent the diversity of U.S. patients.

FDA committee votes against Eli Lilly cancer treatment over concerns trials conducted only in China

Eli Lilly and Co. LLY, -1.49% said late Thursday it has inked a deal with the U.S. government to supply up to 600,000 doses of its investigational COVID-19 drug bebtelovimab for at least $720 million. The U.S. will accept the doses once the FDA grants the treatment an emergency-use authorization, the company said.

Lilly to supply up to U.S. 600,000 doses of COVID-19 treatment

INDIANAPOLIS, Feb. 10, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million. The U.S. government will accept the doses of bebtelovimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options

GlaxoSmithKline

Vir Biotechnology

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's LLY COVID-19 treatments. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

INDIANAPOLIS, Feb. 10, 2022 /PRNewswire/ -- The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY), has elected Cynthia Cardona as its president. Additionally, Lilly has selected Cardona to serve as senior director of social impact for the company.

Cynthia Cardona Elected as President of the Lilly Foundation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Partners With Lilly to Develop Its Tests as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly's Pipeline Programs

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly's Pipeline Programs

Among Big Pharma stocks, the best performers last year were Eli Lilly and Co. ( LLY , Financial), Pfizer Inc. ( PFE , Financial) and AbbVie Inc.( ABBV , Financial), according to an analysis by the pharmaceutical consulting group Evaluate. At the other end of the spectrum were Novartis ( NVS , Financial), Merck & Co. Inc. ( MRK , Financial) and Bristol-Myers Squibb Co. ( BMY , Financial), all of which suffered big market cap declines.

Eli Lilly Saw Highest Share Gain Among Big Pharma in 2021

Bristol-Myers

Merck

Regeneron Pharmaceuticals

Should investors be putting these pharmaceutical stocks on their watchlists?

4 Pharmaceutical Stocks To Watch In February 2022￼

Amgen

Pfizer

A few big biopharma names were on the move Tuesday morning, and analysts are taking their shot at them.

3 Big Biopharma Stocks to Watch on Tuesday

The FDA recently revoked Emergency Use Authorization of their COVID-19 treatments.

This Will Put a Big Dent in Eli Lilly's and Regeneron's Sales This Year

Eli Lilly reported its financial results for the fiscal fourth quarter on Thursday.

Eli Lilly brings in over $1.0 billion in quarterly COVID-19 antibody sales

Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.

Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales

Eli Lilly and Company (LLY) CEO David Ricks on Q4 2021 Results - Earnings Call Transcript

We see the pushback of donanemab's accelerated approval submission as a speed bump because the long-term opportunity has not changed.

Cramer's Investing Club: Buy Eli Lilly's drop on drug delay news because it won't matter long term

Eli Lilly And Co  LLY has posted Q4 sales of $7.9 billion, beating the consensus of $6.90 billion and increasing 8% Y/Y. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Covid-19 antibodies revenue was $1.06 billion in the quarter, up 22% from a year earlier and higher than Wall Street forecasts.

Eli Lilly's Earnings Top Forecasts and 2022 Outlook Is Maintained

Shares of Eli Lilly & Co. LLY, +1.03% rose 0.4% in premarket trading Thursday, after the drug giant reported fourth-quarter profit and revenue that rose above expectations, as COVID-19 antibodies revenue topped $1 billion, which was well above forecasts. Net income fell to $1.73 billion, or $1.90 a share, from $2.12 billion, or $2.32 a share, in the year-ago period.

News for Eli Lilly Stock (LLY)